These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11929691)

  • 1. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).
    Bell JM; Turnidge JD; Gales AC; Pfaller MA; Jones RN;
    Diagn Microbiol Infect Dis; 2002 Mar; 42(3):193-8. PubMed ID: 11929691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).
    Hirakata Y; Matsuda J; Miyazaki Y; Kamihira S; Kawakami S; Miyazawa Y; Ono Y; Nakazaki N; Hirata Y; Inoue M; Turnidge JD; Bell JM; Jones RN; Kohno S;
    Diagn Microbiol Infect Dis; 2005 Aug; 52(4):323-9. PubMed ID: 16165001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance.
    Hansen DS; Schumacher H; Hansen F; Stegger M; Hertz FB; Schønning K; Justesen US; Frimodt-Møller N;
    Scand J Infect Dis; 2012 Mar; 44(3):174-81. PubMed ID: 22364227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.
    Bell JM; Chitsaz M; Turnidge JD; Barton M; Walters LJ; Jones RN
    J Clin Microbiol; 2007 May; 45(5):1478-82. PubMed ID: 17344367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extended-spectrum beta-lactamase production by Enterobacteriaceae isolates from urine cultures of outpatients: results of a 7-year follow-up].
    Çelikbilek N; Gözalan A; Özdem B; Kırca F; Açıkgöz ZC
    Mikrobiyol Bul; 2015 Apr; 49(2):259-65. PubMed ID: 26167826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.
    Winokur PL; Canton R; Casellas JM; Legakis N
    Clin Infect Dis; 2001 May; 32 Suppl 2():S94-103. PubMed ID: 11320450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.
    Kader AA; Kumar A
    Ann Saudi Med; 2005; 25(3):239-42. PubMed ID: 16119526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended spectrum beta-lactamase and metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal.
    Nepal K; Pant ND; Neupane B; Belbase A; Baidhya R; Shrestha RK; Lekhak B; Bhatta DR; Jha B
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):62. PubMed ID: 28927454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.
    Shahid M; Malik A; Akram M; Agrawal LM; Khan AU; Agrawal M
    Int J Infect Dis; 2008 May; 12(3):256-64. PubMed ID: 17981482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
    Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
    Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic detection and occurrence of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli at a tertiary hospital in Trinidad & Tobago.
    Akpaka PE; Swanston WH
    Braz J Infect Dis; 2008 Dec; 12(6):516-20. PubMed ID: 19287841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the Phoenix automated microbiology system for detecting extended-spectrum beta-lactamase in Escherichia coli, Klebsiella species and Proteus mirabilis].
    Lee KK; Kim ST; Hong KS; Huh HJ; Chae SL
    Korean J Lab Med; 2008 Jun; 28(3):185-90. PubMed ID: 18594169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of extended-spectrum beta-lactamase in Klebsiellae pneumoniae and Escherichia coli from China.
    Xiong Z; Zhu D; Wang F; Zhang Y; Okamoto R; Inoue M
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):195-200. PubMed ID: 12458128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the MicroScan NegCombo panel Type 44 for detection of extended-spectrum beta-lactamase among clinical isolates of Escherichia coli, Klebsiella species, and Proteus mirabilis].
    Ko SY; Chung JW; Song AJ; Yoon NS; Sung H; Kim MN
    Korean J Lab Med; 2009 Feb; 29(1):35-40. PubMed ID: 19262076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.